The research on targeted drugs for primary lung cancer has developed rapidly in recent years. Among them，epidermal growth factor receptor-tyrosine kinase inhibitors（EGFR-TKI），which aim on the EGFR gene target，can affect the vast majority of EGFR mutation patients and have good effect. However，EGFR-TKIs have little effect on patients with wild-type or drug-resistant mutations. Therefore，EGFR mutation status detected is needed before targeted therapy. 18F-fluorodeoxyglucose（18F-FDG）positron emission tomography/computed tomography（PET/CT）can predict EGFR mutation status in patients who are not eligible for invasive genetic testing. This article reviewed the research progress of 18F-FDG PET/CT imaging in the prediction of EGFR gene mutation status in lung adenocarcinoma.